NanoMonitor

A miniature electronic biosensor for glycan biomarker detection

Vinay J. Nagaraj, Srivatsa Aithal, Seron Eaton, Manish Bothara, Peter Wiktor, Shalini Prasad

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Aim: The goal of our research is to develop an ultrasensitive diagnostic platform called 'NanoMonitor to enable rapid label-free analysis of a highly promising class of biomarkers called glycans (oligosaccharide chains attached to proteins) with high sensitivity and selectivity. The glycosylation of fetuin - a serum protein - and extracts from a human pancreatic cancer line was analyzed to demonstrate the capabilities of the NanoMonitor. Material & methods: The NanoMonitor device consists of a silicon chip with an array of gold electrodes forming multiple sensor sites and works on the principle of electrochemical impedance spectroscopy. Each sensor site is overlaid with a nanoporous alumina membrane that forms a high density of nanowells on top of each electrode. Lectins (proteins that bind to and recognize specific glycan structures) are conjugated to the surface of the electrode. When specific glycans from a test sample bind to lectins at the base of each nanowell, a perturbation of electrical double-layer occurs, which results in a change in the impedance. Using the lectins Sambucs nigra agglutinin (SNA) and Maackia amurensis agglutinin (MAA), subtle variations to the glycan chains of fetuin were investigated. Protein extracts from BXPC-3, a cultured human pancreatic cancer cell line were also analyzed for binding to SNA and MAA lectins. The performance of the NanoMonitor was compared to a conventional laboratory technique: lectin-based enzyme linked immunosorbent assay (ELISA). Results & discussion: The NanoMonitor was used to identify glycoform variants of fetuin and global differences in glycosylation of protein extracts from cultured human pancreatic cancerous versus normal cells. While results from NanoMonitor correlate very well with results from lectin-based ELISA, the NanoMonitor is rapid, completely label free, requires just 10 μl of sample, is approximately five orders of magnitude more sensitive and highly selective over a broad dynamic range of glycoprotein concentrations. Conclusion: Based on its performance metrics, the NanoMonitor has excellent potential for development as a point-of-care handheld electronic biosensor device for routine detection of glycan biomarkers from clinical samples.

Original languageEnglish (US)
Pages (from-to)369-378
Number of pages10
JournalNanomedicine
Volume5
Issue number3
DOIs
StatePublished - Apr 1 2010

Fingerprint

Biosensing Techniques
Biomarkers
Lectins
Biosensors
Polysaccharides
biomarker
Agglutinins
electronics
Fetuins
protein
Proteins
Maackia
cancer
electrode
Glycosylation
Immunosorbents
Electrodes
Pancreatic Neoplasms
gold
performance

Keywords

  • Cancer glycoprofiling
  • Glycosensor
  • Label-free glycosylation analysis
  • Lectin
  • Lectrochemical impedance spectroscopy glycoprotein analysis

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Cite this

Nagaraj, V. J., Aithal, S., Eaton, S., Bothara, M., Wiktor, P., & Prasad, S. (2010). NanoMonitor: A miniature electronic biosensor for glycan biomarker detection. Nanomedicine, 5(3), 369-378. https://doi.org/10.2217/nnm.10.11

NanoMonitor : A miniature electronic biosensor for glycan biomarker detection. / Nagaraj, Vinay J.; Aithal, Srivatsa; Eaton, Seron; Bothara, Manish; Wiktor, Peter; Prasad, Shalini.

In: Nanomedicine, Vol. 5, No. 3, 01.04.2010, p. 369-378.

Research output: Contribution to journalArticle

Nagaraj, VJ, Aithal, S, Eaton, S, Bothara, M, Wiktor, P & Prasad, S 2010, 'NanoMonitor: A miniature electronic biosensor for glycan biomarker detection', Nanomedicine, vol. 5, no. 3, pp. 369-378. https://doi.org/10.2217/nnm.10.11
Nagaraj, Vinay J. ; Aithal, Srivatsa ; Eaton, Seron ; Bothara, Manish ; Wiktor, Peter ; Prasad, Shalini. / NanoMonitor : A miniature electronic biosensor for glycan biomarker detection. In: Nanomedicine. 2010 ; Vol. 5, No. 3. pp. 369-378.
@article{4c65f6bd9e8947618f673ac1582f1be2,
title = "NanoMonitor: A miniature electronic biosensor for glycan biomarker detection",
abstract = "Aim: The goal of our research is to develop an ultrasensitive diagnostic platform called 'NanoMonitor to enable rapid label-free analysis of a highly promising class of biomarkers called glycans (oligosaccharide chains attached to proteins) with high sensitivity and selectivity. The glycosylation of fetuin - a serum protein - and extracts from a human pancreatic cancer line was analyzed to demonstrate the capabilities of the NanoMonitor. Material & methods: The NanoMonitor device consists of a silicon chip with an array of gold electrodes forming multiple sensor sites and works on the principle of electrochemical impedance spectroscopy. Each sensor site is overlaid with a nanoporous alumina membrane that forms a high density of nanowells on top of each electrode. Lectins (proteins that bind to and recognize specific glycan structures) are conjugated to the surface of the electrode. When specific glycans from a test sample bind to lectins at the base of each nanowell, a perturbation of electrical double-layer occurs, which results in a change in the impedance. Using the lectins Sambucs nigra agglutinin (SNA) and Maackia amurensis agglutinin (MAA), subtle variations to the glycan chains of fetuin were investigated. Protein extracts from BXPC-3, a cultured human pancreatic cancer cell line were also analyzed for binding to SNA and MAA lectins. The performance of the NanoMonitor was compared to a conventional laboratory technique: lectin-based enzyme linked immunosorbent assay (ELISA). Results & discussion: The NanoMonitor was used to identify glycoform variants of fetuin and global differences in glycosylation of protein extracts from cultured human pancreatic cancerous versus normal cells. While results from NanoMonitor correlate very well with results from lectin-based ELISA, the NanoMonitor is rapid, completely label free, requires just 10 μl of sample, is approximately five orders of magnitude more sensitive and highly selective over a broad dynamic range of glycoprotein concentrations. Conclusion: Based on its performance metrics, the NanoMonitor has excellent potential for development as a point-of-care handheld electronic biosensor device for routine detection of glycan biomarkers from clinical samples.",
keywords = "Cancer glycoprofiling, Glycosensor, Label-free glycosylation analysis, Lectin, Lectrochemical impedance spectroscopy glycoprotein analysis",
author = "Nagaraj, {Vinay J.} and Srivatsa Aithal and Seron Eaton and Manish Bothara and Peter Wiktor and Shalini Prasad",
year = "2010",
month = "4",
day = "1",
doi = "10.2217/nnm.10.11",
language = "English (US)",
volume = "5",
pages = "369--378",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - NanoMonitor

T2 - A miniature electronic biosensor for glycan biomarker detection

AU - Nagaraj, Vinay J.

AU - Aithal, Srivatsa

AU - Eaton, Seron

AU - Bothara, Manish

AU - Wiktor, Peter

AU - Prasad, Shalini

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Aim: The goal of our research is to develop an ultrasensitive diagnostic platform called 'NanoMonitor to enable rapid label-free analysis of a highly promising class of biomarkers called glycans (oligosaccharide chains attached to proteins) with high sensitivity and selectivity. The glycosylation of fetuin - a serum protein - and extracts from a human pancreatic cancer line was analyzed to demonstrate the capabilities of the NanoMonitor. Material & methods: The NanoMonitor device consists of a silicon chip with an array of gold electrodes forming multiple sensor sites and works on the principle of electrochemical impedance spectroscopy. Each sensor site is overlaid with a nanoporous alumina membrane that forms a high density of nanowells on top of each electrode. Lectins (proteins that bind to and recognize specific glycan structures) are conjugated to the surface of the electrode. When specific glycans from a test sample bind to lectins at the base of each nanowell, a perturbation of electrical double-layer occurs, which results in a change in the impedance. Using the lectins Sambucs nigra agglutinin (SNA) and Maackia amurensis agglutinin (MAA), subtle variations to the glycan chains of fetuin were investigated. Protein extracts from BXPC-3, a cultured human pancreatic cancer cell line were also analyzed for binding to SNA and MAA lectins. The performance of the NanoMonitor was compared to a conventional laboratory technique: lectin-based enzyme linked immunosorbent assay (ELISA). Results & discussion: The NanoMonitor was used to identify glycoform variants of fetuin and global differences in glycosylation of protein extracts from cultured human pancreatic cancerous versus normal cells. While results from NanoMonitor correlate very well with results from lectin-based ELISA, the NanoMonitor is rapid, completely label free, requires just 10 μl of sample, is approximately five orders of magnitude more sensitive and highly selective over a broad dynamic range of glycoprotein concentrations. Conclusion: Based on its performance metrics, the NanoMonitor has excellent potential for development as a point-of-care handheld electronic biosensor device for routine detection of glycan biomarkers from clinical samples.

AB - Aim: The goal of our research is to develop an ultrasensitive diagnostic platform called 'NanoMonitor to enable rapid label-free analysis of a highly promising class of biomarkers called glycans (oligosaccharide chains attached to proteins) with high sensitivity and selectivity. The glycosylation of fetuin - a serum protein - and extracts from a human pancreatic cancer line was analyzed to demonstrate the capabilities of the NanoMonitor. Material & methods: The NanoMonitor device consists of a silicon chip with an array of gold electrodes forming multiple sensor sites and works on the principle of electrochemical impedance spectroscopy. Each sensor site is overlaid with a nanoporous alumina membrane that forms a high density of nanowells on top of each electrode. Lectins (proteins that bind to and recognize specific glycan structures) are conjugated to the surface of the electrode. When specific glycans from a test sample bind to lectins at the base of each nanowell, a perturbation of electrical double-layer occurs, which results in a change in the impedance. Using the lectins Sambucs nigra agglutinin (SNA) and Maackia amurensis agglutinin (MAA), subtle variations to the glycan chains of fetuin were investigated. Protein extracts from BXPC-3, a cultured human pancreatic cancer cell line were also analyzed for binding to SNA and MAA lectins. The performance of the NanoMonitor was compared to a conventional laboratory technique: lectin-based enzyme linked immunosorbent assay (ELISA). Results & discussion: The NanoMonitor was used to identify glycoform variants of fetuin and global differences in glycosylation of protein extracts from cultured human pancreatic cancerous versus normal cells. While results from NanoMonitor correlate very well with results from lectin-based ELISA, the NanoMonitor is rapid, completely label free, requires just 10 μl of sample, is approximately five orders of magnitude more sensitive and highly selective over a broad dynamic range of glycoprotein concentrations. Conclusion: Based on its performance metrics, the NanoMonitor has excellent potential for development as a point-of-care handheld electronic biosensor device for routine detection of glycan biomarkers from clinical samples.

KW - Cancer glycoprofiling

KW - Glycosensor

KW - Label-free glycosylation analysis

KW - Lectin

KW - Lectrochemical impedance spectroscopy glycoprotein analysis

UR - http://www.scopus.com/inward/record.url?scp=77951240997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951240997&partnerID=8YFLogxK

U2 - 10.2217/nnm.10.11

DO - 10.2217/nnm.10.11

M3 - Article

VL - 5

SP - 369

EP - 378

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 3

ER -